You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Last week, GenomeWeb's readers were most interested in Ginkgo Bioworks' plans to build a sequencing-based coronavirus testing infrastructure.
For the three months ended Dec. 31, 2019, the firm reported total revenues from continuing operations of $1.9 million compared to $1.7 million in Q4 2018.
The ancestor of a bat coronavirus may have obtained a receptor binding motif found among pangolin coronaviruses through a recombination event.
Sema4 said it will provide SARS-CoV-2 viral and antibody testing to Connecticut residents including state employees and first responders.
Presentations at the American Society of Clinical Oncology's virtual annual meeting included new findings relevant to both blood- and spinal fluid-based approaches.
Two studies presented at ASCO's virtual annual meeting demonstrated the clinical utility of germline findings in guiding treatment decisions in cancer.
Breast cancer risk in carriers of pathogenic CHEK2 variants may be classified as low, moderate, or high by adding in polygenic risk score and family history data.
The INFORM study echoed the 2019 interim results from the NCI Pediatric MATCH trial, which found that 24 percent of participants were eligible for targeted treatment.
The template describes the data and information that should be submitted for EUA of collection kits or tests with a home self-collection component.
The researchers also found that COVID-19 patients had a special trigger host immune response in certain pathways, such as interferon gamma signaling.
Investigators explored population dynamics during the shift to farming with new sequence data from more than 100 individuals from present-day France and Germany.
News items for the week of May 25, 2020.
A new microbiome analysis uncovered cancer type-specific bacterial community features, along with intracellular bacteria in tumor and associated immune cells.
The investment bank gave shares of the Temple City, California-based genetic testing company a buy rating and a $20 price target.
The deal will join Tangen's GeneSpark point-of-care instrument with LabWare's portable disease surveillance kit for SARS-CoV-2.
The company said that a large portion of the offering's proceeds would be used to end criminal and civil investigations over its past billing practices.
The test uses a proprietary at-home PCR nasal swab test with a turnaround time of 24 hours and is authorized for use by at-risk people.
The company is also working on a diagnostic COVID-19 test, called LamPore, that will run on its MinIon and GridIon nanopore sequencing platforms
Independent research teams have tackled the genetic history of the Levant, Anatolia, and other parts of the Near East to retrace population movement and mixing since the Bronze Age.
The findings suggested recovered patients could still be viral carriers and might benefit from further monitoring after their release from the hospital.
The company said that by the end of June it would have made available more than 500,000 kits, which allow individuals to self-collect nasal samples at home.
Including the new round, the maker of software to support precision oncology care and drug discovery has landed nearly $100 million in equity investments to date.
More than 70 percent of labs surveyed experienced supply chain interruptions, forcing them to validate three or more diagnostic testing methods.
The Washington Post reports on researchers' efforts to determine the effect of an increasingly common SARS-CoV-2 mutation.
Florida Politics reports Florida's law barring life, long-term care, and disability insurers from using genetic information in coverage decisions went into effect at the beginning of July.
A new analysis finds a link between popular media coverage of a scientific study and how often that paper is cited.
In Nature this week: CRISPR approaches to editing plant genomes, way to speed up DNA-PAINT, and more.